Interview: Achilles Advances Armed With £100m
After receiving major backing for its strategy of targeting clonal neoantigens, Achilles's CEO tells Scrip that the UK firm's manufacturing prowess gives it an edge over competitors.
After receiving major backing for its strategy of targeting clonal neoantigens, Achilles's CEO tells Scrip that the UK firm's manufacturing prowess gives it an edge over competitors.